By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Achillion Pharmaceuticals, Inc. 

300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-7000 Fax: 203-624-7003



Drug Discovery

Company News
Achillion (ACHN) Reports First Quarter 2017 Financial Results And Provides Update On Clinical Programs 5/4/2017 11:48:48 AM
Achillion (ACHN) Announces Additional Phase II Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178 4/24/2017 8:16:58 AM
Achillion (ACHN) Announces Initiation Of Patient Dosing In Phase II Study Of ACH-4471 For Paroxysmal Nocturnal Hemoglobinuria 4/6/2017 11:18:55 AM
USPTO Grants Composition Of Matter Patent To Achillion (ACHN) For Small Molecule Complement Alternative Pathway Factor D Inhibitors 3/22/2017 8:41:04 AM
Achillion (ACHN) Reports 2016 Fourth Quarter And Year-End Financial Results 2/24/2017 7:55:34 AM
IDBS E-WorkBook For Chemistry Enables Achillion (ACHN) To Go Paperless 2/8/2017 8:22:02 AM
Moving From Big Pharma To Biotech—A Conversation With Achillion (ACHN)'s CSO 2/1/2017 6:01:31 AM
Achillion (ACHN) Scores $15 Million Clinical Milestone From Janssen R&D for the Advancement of JNJ-4178 in Phase 2B 12/28/2016 7:44:56 AM
Achillion (ACHN) Release: Data Presented At American Society of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases 12/6/2016 8:02:03 AM
Achillion (ACHN) Announces Initiation Of Patient Dosing By Janssen Pharmaceutical In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV 11/30/2016 7:58:23 AM